Shingles is latest target of Covid vaccine makers Pfizer and BioNTech

Meanwhile, shares in biotech company Valneva fell again in Paris trade on Wednesday, declining for the seventh day in a row

Pfizer partnered with BioNTech in 2018 for an influenza vaccine and again in 2020 to develop the Covid-19 vaccine that has been used across the world and has brought in billions in sales for the companies.

Pfizer and BioNTech said they will develop a potential mRNA-based vaccine for the prevention of viral infection shingles, collaborating for the third time after the success of their Covid-19 vaccine.

Pfizer partnered with BioNTech in 2018 for an influenza vaccine and again in 2020 to develop the Covid-19 vaccine that has been used across the world and has brought in billions in sales for the companies.